[SF Business Times ] Three takeaways from Gilead’s Hepatitis C challenge

1. It’s all about price — even when it’s not: Even before Foster City-based Gilead Sciences Inc., led by CEO John Martin, launched its hepatitis C drug Sovaldi for $1,000 a pill, critics pounced.

Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.